News | June 25, 2024
Arkema grants technology license to Seqens to manufacture PEKK for sale in medical implantable applications
PEKK is a high-performance polymer family used in aerospace and other demanding markets
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Subscribe To Our Newsletter & Stay Updated
